Almirall’s Lebrikizumab Shows Long-Term Efficacy
Company Announcements

Almirall’s Lebrikizumab Shows Long-Term Efficacy

Almirall (ES:ALM) has released an update.

Almirall has announced that its dermatological treatment, lebrikizumab, has shown sustained efficacy over three years in patients with moderate to severe atopic dermatitis, maintaining clear or almost clear skin in more than 80% of individuals. The treatment, which is a monthly maintenance dose, has also reduced the need for other potent treatments in the majority of patients. These results, consistent with previous safety profiles, will be presented at the EADV Congress in Amsterdam.

For further insights into ES:ALM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Spain Auto-Generated NewsdeskAlmirall to Present 9-Month 2024 Financial Results
Brian Anderson0O9B Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App